Kiniksa officer plans sale of 4,600 shares, $369K

An officer of Kiniksa Pharmaceuticals International, plc filed a Rule 144 notice to sell 4,600 Class A ordinary shares related to equity compensation.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has a notice of proposed sale under Rule 144 by officer Michael R. Megna for up to 4,600 Class A ordinary shares of Kiniksa, to be sold through Charles Schwab & Co., Inc.

The filing lists an aggregate market value of $369,380.00 for these shares and states that 48,289,273 Class A ordinary shares were outstanding at the referenced time; this is a baseline figure, not the amount being sold. The shares to be sold relate to a restricted stock lapse on September 1, 2026, categorized as equity compensation.

Key Figures

Shares proposed for sale: 4,600 Class A ordinary shares Aggregate market value: $369,380.00 Shares outstanding: 48,289,273 Class A ordinary shares +1 more

4 metrics

Shares proposed for sale 4,600 Class A ordinary shares Maximum number of Kiniksa shares covered by the Rule 144 notice

Aggregate market value $369,380.00 Total market value reported for the 4,600 shares proposed for sale

Shares outstanding 48,289,273 Class A ordinary shares Kiniksa Class A ordinary shares outstanding as reported in the filing

Restricted stock lapse date September 1, 2026 Date tied to the equity compensation from which the shares to be sold arise

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 regulatory

"notice of proposed sale under Rule 144 by officer Michael R. Megna"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Class A ordinary shares | 09/01/2026 | Restricted Stock Lapse"

Equity Compensation financial

"09/01/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for KNSA?

The filing discloses that officer Michael R. Megna intends to sell up to 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc (KNSA) under Rule 144, with the shares held at Charles Schwab & Co., Inc.

How many KNSA shares are covered by this Rule 144 notice?

The notice covers up to 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc. This amount reflects the proposed maximum number of shares to be sold under the Rule 144 filing for the account of Michael R. Megna.

What is the aggregate market value of the KNSA shares in this Form 144?

The filing reports an aggregate market value of $369,380.00 for the 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc that are proposed to be sold under Rule 144.

How many KNSA shares were outstanding according to this filing?

The filing states that 48,289,273 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc were outstanding. This figure provides context on the company’s share base and is separate from the 4,600 shares proposed for sale.

What is the origin of the KNSA shares being sold under this Form 144?

The shares are tied to a restricted stock lapse on September 1, 2026 from Kiniksa Pharmaceuticals International, plc and are categorized as equity compensation in the filing’s securities-to-be-sold section.

On which market are the KNSA shares listed in this Rule 144 filing?

The filing identifies the Class A ordinary shares of Kiniksa Pharmaceuticals International, plc as listed on NASDAQ, providing the principal market for the securities covered by this Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:03 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:02 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001464583
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Megna Michael R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	4600	369380.00	48289273	09/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	09/01/2026	Restricted Stock Lapse	Kiniksa Pharmaceuticals International, plc			4600	09/01/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/24/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Michael R Megna
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)